Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Glioma 5Neuroendocrine Tumors 2Glioblastoma 2Sarcoma 1Parkinson Disease 1Parathyroid Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Gliosarcoma 1Glioma, Subependymal 1Ependymoma 1Congenital Hyperinsulinism 1Carcinoma, Medullary 1Brain Neoplasms 1Astrocytoma 1

Interventions

fluorodopa F 18 1Neurofeedback 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Parkinson Disease × fluorodopa F 18 × Clear all
NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡